Market Highlights
According to MRFR analysis, Human
Immunodeficiency Virus (HIV) Drugs Market is expected to register a CAGR
of 5% during the forecast period of 2019 to 2025 and was valued at USD
24 million in 2018.
HIV drugs aim to control
the growth of the human immunodeficiency virus (HIV), improve the patient’s
overall immune system, and reduce/stop the symptoms. The drugs used to treat
HIV infection are antiretrovirals, which help reduce the viral load and fight
the infection.
The growth of the global HIV drug
market is driven by the increasing prevalence of HIV infection, rising
awareness of HIV treatment, and the launch of innovative drugs. However,
stringent regulatory policies for drug approval and product recalls are
expected to curb the growth of the global HIV drug market during the assessment
period. The global Human Immunodeficiency Virus (HIV) Drugs Market is currently
dominated by several market players. The key players are involved in product
launches and strategic collaborations to strengthen their market positions.
Segmentation
The global HIV drug market has been
segmented based on type and end-user. The market, based on type, has been
divided into nucleoside reverse transcriptase inhibitors (NRTIs),
non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors
(PIs), fusion inhibitors, CCR5 antagonists, integrase inhibitors,
post-attachment inhibitors, and pharmacokinetic enhancers. The drugs in these different segments differ with respect
to their mechanism of treating the HIV infection. The different approaches for treatment
are, inhibiting HIV’s reverse transcriptase, preventing HIV maturation, and
preventing the entry of the virus into the host cells, among others. The global
Human Immunodeficiency Virus (HIV) Drugs Market has been segmented based on
end-user, into hospitals & clinics, specialty centers, and others. The
hospitals & clinics segment is expected to hold the largest market share
due to an increasing number of hospitals.
Key Players
Some of the key players
in the Global Human Immunodeficiency Virus (HIV) Drugs Market are Boehringer
Ingelheim International, GmbH (Germany), Cipla Inc. (India), Merck & Co.,
Inc. (US), AbbVie Inc. (US), Bristol-Myers Squibb Company (US), Teva
Pharmaceutical Industries Ltd (Israel), Gilead Sciences, Inc. (US),
F.Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Aurobindo Pharma
(India), Celltrion Healthcare Co., Ltd (South Korea), and ViiV Healthcare (UK).
Regional Analysis
The market has been divided, by
region, into Europe, the Americas, Asia-Pacific, and the Middle East &
Africa. The Americas holds the largest market share. The Human Immunodeficiency
Virus (HIV) Drugs Market in the Americas has further been branched into North
America and Latin America, with the North American market divided into the US
and Canada. Europe is expected to be the second-largest market owing to factors
such as product launches by key players. The European Human Immunodeficiency
Virus (HIV) Drugs Market has been categorized as Western Europe and Eastern
Europe. The Western European market has further been classified as Germany,
France, the UK, Italy, Spain, and the rest of Western Europe. The Human
Immunodeficiency Virus (HIV) Drugs Market in Asia-Pacific has been segmented
into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
Due to the growing awareness regarding the use of HIV drugs and the increasing
incidence of HIV in the region, the market in Asia-Pacific is expected to be
the fastest-growing. The Human Immunodeficiency Virus (HIV) Drugs Market in the
Middle East & Africa has been divided into the Middle East and Africa and
is expected to hold the least market share.
No comments:
Post a Comment